

ORIGINAL

PART B - FEE(S) TRANSMITTAL

plete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or Fax (703) 746-4000

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks I through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block I)

7590

04/20/2004

Melissa A Shaw Patent Department Bayer Corporation 800 Dwight Way P O Box 1986 Berkeley, CA 94701

Note: A conflicate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission
I hereby certify that this Fec(s) Transmittal is being deposited with the United
States Postal Service with sufficient postage for first class mail in an envelope
addressed to the Mail Stop ISSUE FEE address above, or being facsimile
transmitted to the USPTO, on the date indicated below.

(Depositors name
(Signature
(Date

- (APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
	09/671,773	09/27/2000	Clark Pan	MSB-7272	7437

TITLE OF INVENTION: PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP)RECEPTOR 3 (R3) AGONISTS AND THEIR PHATMACOLOGICAL METHODS OF USE

APPLN. TYPE	SMALL ENTITY	ISSUE F	EE	PUBLICATION FEE	TOTAL PEE(S) DUE	DATE DUE
nonprovisional	NO	\$1330)	\$0	\$1330	07/20/2004
EXAMINER MORAN, MARJORIE A		ART UNIT		CLASS-SUBCLASS	ו	
		1631		530-324000	٠ .	
☐ Change of correspond Address form PTO/SB/	cc address or indication of "F dence address (or Change of (122) attached. tion (or "Fee Address" Indica or more recent) attached. Us	Correspondence :	names of agents Of firm (have agent) and	nting on the patent front page, up to 3 registered patent a L alternatively, (2) the name tog as a member a registered i the names of up to 2 regist or agents. If no name is liste need.	of a single attorney or 2	M. Pellegrino
. ASSIGNEE NAME AN	D RESIDENCE DATA TO B	E PRINTED ON T	HE PATENT	(print or type)		
PLEASE NOTE: Unles	s an assignee is identified be ed to the USPTO or is being :	low, no assignee di submitted under sep	ata will appearance cover.	ar on the patent, inclusion of a Completion of this form is NO. E: (CITY and STATE OR CO	i a substitute for tiling an ass	ate when an assignment h ignment.
Bayer Pharmac	euticals Corporation		West Ha	iven, Connecticut, U.S	.	
lease check the appropriate	c assigned category or catego	rics (will not be pri	nted on the p	atent); 🔾 individual 🔀 c	corporation or other private gr	oup entity 🕒 governmen
u. The following fee(s) are			Payment of		vipoladar di vinet private gi	orb entity a governmen
XIssue Poe				the amount of the fee(s) is end	inseri	
Publication Fee				y credit card. Form PTO-2038		
Advance Order - # of Copies			The Direc	tor is hereby authorized by ch	sares the required fee(s) or	credit any overpayment, r

Director for Patents is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.

(Authorized Signature) Susan M. Pelledrino (Man W. Killagiro (Date) 11/01/2004 Reg. No. 48,972 NOTE: The Issue Fee and Publication Fee (if rectaired) will not be accepted from anyone other than the applicant; a registered autorney of agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Alexandria, Virginia 22313-1450. DO NOT SEND FERS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

11/01/2004 HDEMESS2 00000043 133372 09671773


01 FC:1501

1370.00 DA

TRANSMIT THIS FORM WITH FEE(S)

PTOL-85 (Rev. 11/03) Approved for use through 04/30/2004.

OMB 0651-0033 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE





To:	Mail Stop Issue Fee United States Patent and Trademark Office					
Fax:	(703) 746-4000	Pages: 9 (including cover)				
Date:	November 1, 2004					
From:	Jill Durante					
Fax:	(203) 812-6459	Tel.: (203) 812-6449				

Fax

RE:

Application No. 09/671,773

ATTACHMENTS:

- -Correction of Issue Fee Transmittal Letter
- -Part B Fee(s) Transmittal (Form PTOL-85) [IN DUPLICATE]
- -Copy of Part B Fee(s) Transmittal (Form PTOL-85), Issue Fee Transmittal and Postcard submitted to USPTO on 07/16/2004
- -Certificate of Transmission under 37 CFR 1.8
- -Fax Cover Sheet

Bayer HealthCare LLC

400 Morgan Lane West Haven, CT 06516

Phone: (203) 812-6449 Fax: (203) 812-6459

PLEASE ACKNOWLEDGE RECEIPT

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND EXEMPT FROM DISCLOSURE. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR AN EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING THE MESSAGE TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT THE PRIVILEGED OR CONFIDENTIAL NATURE OF THIS MESSAGE IS NOT WAIVED BY INADVERTENT DISCLOSURE. ANY DISSEMINATION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

NOV Q1

PTO/SB/97 (05-03)
Approved for use through 04/30/2003, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to reapond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on November 1, 2004 Date	
	fu Duranto Signature
	Jill Durante Typed or printed name of person signing Certificate

Bayer Pharmaceuticals Corporation 400 Morgan Lane West Haven, CT 06516 Fax No. (203) 812-6459

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

ATTACHMENTS:

-Correction of Issue Fee Transmittal Letter

-Part B - Fee(s) Transmittal (Form PTOL-85) [IN DUPLICATE]

-Copy of Part B - Fee(s) Transmittal (Form PTOL-85), Issue Fee Transmittal and Postcard submitted to USPTO on 07/16/2004

-Certificate of Transmission under 37 CFR 1.8

-Fax Cover Sheet

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Attorney Docket No. MSB 7272



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

plicant(s):

Bayer Pharmaceuticals Corporation

Group Art Unit: 1631

Serial No .:

09/671,773

Examiner: Moran, Marjorie A.

Filed:

09/27/2000

For:

Pituitary Adenylate Cyclase Activating Peptide (PACAP) Receptor 3 (R3) Agonists and

Their Pharmacological Methods of Use

MAIL STOP ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence and any papers referred to as attached are being facsimile transmitted, on the date shown below, to the United States Patent and Trademark Office, Mail Stop Issue Fee, facsimile number (703) 746-4000.

Date: November 1, 2004

Jill Durante

CORRECTION OF ISSUE FEE TRANSMITTAL LETTER

Sir:

On July 16, 2004, Applicants submitted the issue fee in connection with the above-identified case. Inadvertently, the incorrect Deposit Account Number was listed on the Part B - Fee(s) Transmittal (Form PTOL-85).

Enclosed is a revised Part B - Fee(s) Transmittal (Form PTOL-85) with the correct Deposit Account Number 13-3372. The Commissioner is hereby authorized to charge the total fee(s) due (\$1,330.00) and any other fees that may be due in connection with this request to Deposit Account No. 13-3372.

In addition, enclosed please find a copy of the original Part B - Fee(s) Transmittal (Form PTOL-85), Issue Fee Transmittal Letter and Postcard submitted on July 16, 2004.

Respectfully submitted,

Susan M. Pellegrino Attorney for Applicants

Reg. No. 48,972

Date: November 1, 2004

Bayer Pharmaceuticals Corporation 400 Morgan Lane West Haven, CT 06516-4175

Telephone: Facsimile:

(203) 812-6450 (203) 812-6459





The U.S. Patent & Trademark Office date stamp hereon will acknowledge receipt of the following in Re the application of Pan, et al.; Serial No. 09/671,773; filed: 09/27/2000; entitled "Pituitary Adenylate Cyclase Activating Peptide (PACAP) Receptor 3 (R3) Agonists and Their Pharmacological Methods of Use":

 Part B - Issue Fee Transmittal (Form PTOL-85B DUPLICATE);

Issue Fee Transmittal Letter; and

Return Receipt Postcard.

Date of Deposit: July 16, 2004 First Class Mail Docket No. MSB 7272P2 SMP/id





Attorney Docket No. MSB 7272

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Bayer Pharmaceuticals Corporation

Group Art Unit: 1631

Serial No.:

09/671,773

Examiner: Moran, Marjorie A.

Filed:

09/27/2000

For:

Pituitary Adenylate Cyclase Activating Peptide (PACAP) Receptor 3 (R3)

Agonists and Their Pharmacological Methods of Use

MAIL STOP ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1,8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below. with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Mail Stop ISSUE FEE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: July 16, 2004

ature of person certifying [Jill Durante]

ISSUE FEE TRANSMITTAL LETTER

Sir:

Enclosed please find the following documents in connection with transmittal and payment of the issue fee in the above-identified case:

- Part B Issue Fee Transmittal (Form PTOL-85B) (IN DUPLICATE); and
- Return Receipt Post Card.

Respectfully submitted.

Date: July 16, 2004

Attorney for Applicants Reg. No. 48,972

Bayer Pharmaceuticals Corporation

400 Morgan Lane

West Haven, CT 06516-4175

Telephone: (203) 812-6450 Facsimile: (203) 812-6459